← FDA DRUG APPROVALS

FDA NDA · NDA205626

LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

Sponsor: MICRO LABS

APPLICATION
NDA205626
TYPE
NDA
ORIGINAL APPROVAL
2018-08-13
LATEST ACTION
2018-08-13
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE · ReferenceDiscontinued
LAMIVUDINE 150MG, NEVIRAPINE 200MG, ZIDOVUDINE 300MG · TABLET · ORAL

Approval history

2018-08-13Type 4 - New Combination · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →